指南与共识重症综合管理与镇静镇痛消化、代谢与肾脏急症

造血细胞治疗项目开展嵌合抗原受体T细胞(CAR-T细胞)治疗的前提条件:法语国家骨髓移植与细胞治疗学会(SFGM-TC)指南

[Prerequisite for hematopoietic cellular therapy programs to set up chimeric antigen receptor T-cell therapy (CAR T-cells): Guidelines from the Francophone Society of Bone Marrow Transplantation and Cellular Therapy (SFGM-TC)].
指南 / 共识 · Bull Cancer · 2017-11-23
一句话结论法国SFGM-TC指南提出,医院开展CAR-T细胞临床试验前需满足组织协调前提,尤其强调细胞治疗病房与邻近重症监护病房之间的全面协作以预见和处理严重毒性。

CAR-T细胞是经基因工程表达靶向CD19等肿瘤抗原的嵌合抗原受体自体或异体人淋巴细胞,属于先进治疗药品(ATMP)中的基因治疗药品。其生产和交付组织与造血细胞移植不同。现有临床观察多来自美国或中国开展的试验,显示对晚期或预后不良血液恶性肿瘤疗效显著,但相当比例患者出现严重副作用。毒性可且必须在负责患者的临床细胞治疗病房与邻近重症监护病房之间的全面协调下被预见和处理。本研讨会旨在确定法国医院在启动CAR-T细胞临床试验前需满足的前提条件,以高效组织并符合申办方期望。

要点

  • CAR-T细胞属于先进治疗药品(ATMP)中的基因治疗药品,其生产和交付组织与造血细胞移植不同。
  • 现有临床观察多来自美国或中国开展的试验,显示对晚期或预后不良血液恶性肿瘤疗效显著,但相当比例患者出现严重副作用。
  • 毒性可且必须在负责患者的临床细胞治疗病房与邻近重症监护病房之间的全面协调下被预见和处理。
  • 本研讨会旨在确定法国医院在启动CAR-T细胞临床试验前需满足的前提条件,以高效组织并符合申办方期望。

适用人群与场景

  • 晚期或预后不良血液恶性肿瘤患者(基于现有临床试验观察)

处置流程与药物剂量

  • 毒性可且必须在负责患者的临床细胞治疗病房与邻近重症监护病房之间的全面协调下被预见和处理。

研究设计与关键结果

  • 制定机构:法语国家骨髓移植与细胞治疗学会(SFGM-TC);方法:研讨会确定法国医院在启动CAR-T细胞临床试验前需满足的前提条件;证据分级体系:原文未报告。

证据类型、等级与局限

  • 证据类型:指南(SFGM-TC);推荐强度:原文未报告;局限:原文未报告局限性。

对床旁实践的改变

  • 作者认为,医院在启动CAR-T细胞临床试验前需满足组织前提,包括临床细胞治疗病房与邻近重症监护病房之间的全面协调以预见和处理毒性。

指南或共识出处

  • 法语国家骨髓移植与细胞治疗学会(SFGM-TC)指南,发表于Bull Cancer;年份原文未报告。

提炼说明

  • 本条依据论文摘要整理;摘要未涉及「诊断标准与关键阈值」「红旗征与不能漏的情况」,故未列出这些栏目;全文请点「阅读原文」。
英文原文(摘要)· 点击展开

CAR T-cells are autologous or allogeneic human lymphocytes that are genetically engineered to express a chimeric antigen receptor targeting an antigen expressed on tumor cells such as CD19. CAR T-cells represent a new class of medicinal products, and belong to the broad category of Advanced Therapy Medicinal Products (ATMPs), as defined by EC Regulation 2007-1394. Specifically, they are categorized as gene therapy medicinal products. Although CAR T-cells are cellular therapies, the organization for manufacturing and delivery is far different from the one used to deliver hematopoietic cell grafts, for different reasons including their classification as medicinal products. Currently available clinical observations were mostly produced in the context of trials conducted either in the USA or in China. They demonstrate remarkable efficacy for patients presenting advanced or poor-prognosis hematological malignancies, however with severe side effects in a significant proportion of patients. Toxicities can and must be anticipated and dealt with in the context of a full coordination between the clinical cell therapy ward in charge of the patient, and the neighboring intensive care unit. The present workshop aimed at identifying prerequisites to be met in order for French hospitals to get efficiently organized and fulfill sponsors' expectations before initiation of clinical trials designed to investigate CAR T-cells.

来源:Bull Cancer,查看原文。版权归原作者所有。

参考来源

  1. Yakoub-Agha I, Ferrand C, Chalandon Y, et al. [Prerequisite for hematopoietic cellular therapy programs to set up chimeric antigen receptor T-cell therapy (CAR T-cells): Guidelines from the Francophone Society of Bone Marrow Transplantation and Cellular Therapy (SFGM-TC)]. Bull Cancer. 2017. PMID: 29174320. doi:10.1016/j.bulcan.2017.10.017

供执业医师抢救与诊疗参考,不替代临床判断;剂量请结合体重、肝肾功能和本院药品规格复核,以指南原文为准。